SEC Form 4 · accession 0001144204-16-139012
MusclePharm Corp · MSLP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Ryan Charles Drexler
Officer — See Remarks. · Director · 10% Owner
Period of report
Dec 8, 2016
Accepted (ET)
Dec 12, 2016 · 5:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001415684
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 8, 2016 | A | 550,000 | $0.00 | A | 581,924 | D | |
| Common StockF2 | holding | — | — | — | 1,499,408 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On December 8, 2016, Mr. Drexler was granted 550,000 shares of restricted stock pursuant to the Amended and Restated Executive Employment Agreement between MusclePharm Corporation and Mr. Drexler, dated November 18, 2016. The restricted stock vests in full upon the first anniversary of the grant date.
- F2Represents shares of common stock held by Consac LLC ("Consac"). Mr. Drexler is the Chief Executive Officer of Consac and may be deemed to be the indirect beneficial owner (as that term is defined under Rule 13d-3 of the Securities Exchange Act) of the common stock that Consac beneficially owns. Mr. Drexler has the power to direct the voting and disposition of the Issuer's common stock that Consac beneficially owns.
Remarks
President, Chief Executive Officer and Chairman of the Board of Directors.